Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 6 studies | 23% ± 7% | |
goblet cell | 4 studies | 18% ± 2% | |
enterocyte | 3 studies | 17% ± 2% |
Insufficient scRNA-seq data for expression of ANO9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 1540.49 | 328 / 328 | 94% | 19.82 | 167 / 178 |
lung | 96% | 1183.13 | 555 / 578 | 91% | 18.75 | 1048 / 1155 |
stomach | 74% | 1376.18 | 267 / 359 | 96% | 57.44 | 275 / 286 |
kidney | 100% | 1865.40 | 89 / 89 | 70% | 10.27 | 633 / 901 |
thymus | 95% | 1135.85 | 623 / 653 | 61% | 10.76 | 367 / 605 |
intestine | 56% | 4460.07 | 541 / 966 | 99% | 62.27 | 520 / 527 |
bladder | 52% | 825.76 | 11 / 21 | 93% | 28.98 | 469 / 504 |
breast | 55% | 734.34 | 254 / 459 | 82% | 10.45 | 916 / 1118 |
esophagus | 39% | 911.41 | 559 / 1445 | 95% | 20.22 | 173 / 183 |
prostate | 89% | 1524.73 | 218 / 245 | 44% | 3.40 | 222 / 502 |
lymph node | 0% | 0 | 0 / 0 | 100% | 22.76 | 29 / 29 |
spleen | 100% | 2315.41 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.53 | 1 / 1 |
ovary | 2% | 11.59 | 4 / 180 | 93% | 19.96 | 401 / 430 |
tonsil | 0% | 0 | 0 / 0 | 93% | 17.49 | 42 / 45 |
uterus | 8% | 72.69 | 13 / 170 | 85% | 18.12 | 388 / 459 |
skin | 72% | 5385.50 | 1304 / 1809 | 18% | 2.09 | 87 / 472 |
peripheral blood | 69% | 1293.09 | 637 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 33% | 3.87 | 26 / 80 |
liver | 1% | 7.20 | 3 / 226 | 22% | 4.39 | 89 / 406 |
adipose | 18% | 124.19 | 217 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 2% | 27.75 | 30 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 258 | 1% | 0.12 | 2 / 230 |
heart | 1% | 4.48 | 6 / 861 | 0% | 0 | 0 / 0 |
brain | 0% | 0.48 | 3 / 2642 | 0% | 0.03 | 2 / 705 |
muscle | 0% | 1.10 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0061590 | Biological process | calcium activated phosphatidylcholine scrambling |
GO_0034220 | Biological process | monoatomic ion transmembrane transport |
GO_0061589 | Biological process | calcium activated phosphatidylserine scrambling |
GO_0061591 | Biological process | calcium activated galactosylceramide scrambling |
GO_1902476 | Biological process | chloride transmembrane transport |
GO_0006629 | Biological process | lipid metabolic process |
GO_0051649 | Biological process | establishment of localization in cell |
GO_0005886 | Cellular component | plasma membrane |
GO_0019869 | Molecular function | chloride channel inhibitor activity |
GO_0005515 | Molecular function | protein binding |
GO_0005229 | Molecular function | intracellularly calcium-gated chloride channel activity |
GO_0005254 | Molecular function | chloride channel activity |
GO_0017128 | Molecular function | phospholipid scramblase activity |
Gene name | ANO9 |
Protein name | Anoctamin-9 (Transmembrane protein 16J) (Tumor protein p53-inducible protein 5) (p53-induced gene 5 protein) |
Synonyms | PIG5 TP53I5 TMEM16J |
Description | FUNCTION: Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity . Can inhibit the activity of ANO1 . . |
Accessions | A1A5B4 ENST00000332826.7 [A1A5B4-1] |